Morgan Stanley
SKYE icon

Morgan Stanley’s Skye Bioscience SKYE Stock Holding History

Morgan Stanley’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71K Sell
309
-10
-3% -$63 ﹤0.01% 7438
2026
Q1 		$1.57K Sell
319
-215
-40% -$1.4K ﹤0.01% 7371
2025
Q4 		$3.2K Sell
534
-85
-14% -$993 ﹤0.01% 7151
2025
Q3 		$19.5K Sell
619
-486
-44% -$14.7K ﹤0.01% 6696
2025
Q2 		$37K Sell
1,105
-2,880
-72% -$47.7K ﹤0.01% 6455
2025
Q1 		$50.7K Sell
3,985
-3,643
-48% -$79.6K ﹤0.01% 6262
2024
Q4 		$173K Buy
7,628
+454
+6% +$15.2K ﹤0.01% 5844
2024
Q3 		$224K Buy
7,174
+4,490
+167% +$201K ﹤0.01% 5715
2024
Q2 		$172K Buy
+2,684
New +$255K ﹤0.01% 5745

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Morgan Stanley's SKYE Position: Q2 2026 in Review

Morgan Stanley reduced its Skye Bioscience (SKYE) stake by 3.1% in Q2 2026, selling an estimated $63 and leaving 309 shares worth $1.71K. The position accounts for ﹤0.01% of the portfolio, ranked #7438.

Morgan Stanley first reported a position in SKYE in Q2 2024 and has held it in 9 quarters since. The position peaked at $224K in Q3 2024. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • Morgan Stanley held 309 shares of Skye Bioscience worth $1.71K as of Q2 2026.
  • Morgan Stanley sold 10 Skye Bioscience shares in Q2 2026, an estimated $63.
  • Skye Bioscience made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7438 holding.
  • Morgan Stanley first reported a position in Skye Bioscience in Q2 2024 and has held it in 9 quarters since.
  • Morgan Stanley's Skye Bioscience position peaked at $224K in Q3 2024.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.